FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Front Vet Sci / Equine Umbilical Cord Serum Composition and Its Healing Effe...
Frontiers in veterinary science2022; 9; 843744; doi: 10.3389/fvets.2022.843744

Equine Umbilical Cord Serum Composition and Its Healing Effects in Equine Corneal Ulceration.

Abstract: Human autologous serum (AS) and umbilical cord serum (UCS) both contain growth and neurotrophic factors that promote corneal healing. Unassigned: Our objectives were to compare equine AS and UCS cytokine and growth factor profiles and to assess the safety and clinical feasibility of the therapeutic use of UCS eye drops in cases of spontaneous complex ulcers. Unassigned: Prospective clinical trial. Unassigned: Vitamin A insulin growth factor, platelet-derived growth factor-BB, transforming growth factor (TGF)-β1 (enzyme-linked immunosorbent assay), interleukin (IL)-1β, IL-6, interferon-γ, and monocyte chemoattractant protein 1 concentrations were determined in 10 AS collected from different horses and 10 UCS sampled at delivery. Six client-owned horses presenting with complex non-healing corneal defects of >5 mm2 were included in a clinical trial and treated with conventional therapy and conditioned UCS drops for 8-15 days. Ulcer surface and time to complete epithelialization were recorded. Unassigned: Median concentrations of vitamin A, insulin growth factor, and platelet-derived growth factor-BB were not significantly different in AS compared with UCS (respectively, 14.5 vs. 12.05 μg/ml; 107.8 vs. 107.3 pg/ml; and 369.1 vs. 924.2 pg/ml). TGF-β1 median concentration in UCS was significantly higher than in AS (3,245 vs. 2571pg/ml) (p = 0.04). IL-1β, IL-6, interferon-γ, and monocyte chemoattractant protein 1 concentrations were variable in AS and undetectable in UCS. The corneal median ulcerative area was 37.2 mm2 (6.28-57.14 mm2) and had a duration of 4-186 days (median 19 days). All lesions healed within 13-42 days (median 17 days). No adverse effects nor recurrences within 1 month were noticed. Unassigned: The sample size was small. Spontaneous corneal epithelial defects presented with variable clinical characteristics. There were no age-matched control horses to assess corneal healing time and rate. Unassigned: Equine UCS may be beneficial, as it contains no pro-inflammatory cytokines and a greater concentration of TGF-β1 compared with AS. Topical UCS appears safe and may potentially be used as adjunctive therapy for equine complex non-healing ulcers.
Copyright © 2022 Peyrecave-Capo, Saulnier, Maddens, Gremillet and Desjardins.
Get Full Text
Publication Date: 2022-03-17 PubMed ID: 35372560PubMed Central: PMC8970184DOI: 10.3389/fvets.2022.843744Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research explores the composition of equine umbilical cord serum and its potential therapeutic benefits in treating equine corneal ulcerations. The study compared equine autologous serum (AS) and umbilical cord serum (UCS), assessed their safety and clinical feasibility as treatments, and found that UCS may potentially be used as an adjunctive therapy for difficult-to-treat ulcers.

Research Methodology

  • The researchers conducted a prospective clinical trial in which they measured and compared the vitamin A, insulin growth factor, and platelet-derived growth factor concentrations in ten AS samples from different horses and ten UCS samples taken at the time of delivery.
  • Additionally, they examined transforming growth factor (TGF-β1) concentrations using an enzyme-linked immunosorbent assay, and the levels of interleukin (IL)-1β, IL-6, interferon-γ, and monocyte chemoattractant protein 1.
  • They then conducted a clinical trial with six horses that had complex, non-healing corneal defects, treating them with conventional therapy and the addition of UCS eye drops for a period of 8-15 days. During this time, they monitored the ulcer surface area and time to complete epithelialization.

Findings

  • The study found that the median concentrations of vitamin A, insulin growth factor, and platelet-derived growth factor were not significantly different in AS compared to UCS.
  • However, TGF-β1 median concentration was significantly higher in UCS than in AS, suggesting potential therapeutic benefits. The cytokines IL-1β, IL-6, interferon-γ, and monocyte chemoattractant protein 1, which could potentially induce inflammation, were undetectable in UCS, also indicating possible advantages over AS.
  • In the clinical trial, all corneal ulcers treated with UCS healed within a period of 13-42 days, with no apparent side effects or recurrences reported within one month.

Limitations and Conclusion

  • The researchers acknowledged certain limitations in the study. Notably, the sample size was relatively small and the corneal defects varied in their clinical characteristics. Furthermore, the absence of age-matched control horses in the study hindered direct comparisons of healing time and rate between groups, possibly influencing the reliability of the clinical trial results.
  • Despite these limitations, the study concluded that equine UCS, with its high concentration of TGF-β1 and absence of pro-inflammatory cytokines, might be beneficial for the treatment of equine complex non-healing ulcers and could potentially be used as an adjunctive therapy alongside conventional treatment methods.

Cite This Article

APA
Peyrecave-Capo X, Saulnier N, Maddens S, Gremillet B, Desjardins I. (2022). Equine Umbilical Cord Serum Composition and Its Healing Effects in Equine Corneal Ulceration. Front Vet Sci, 9, 843744. https://doi.org/10.3389/fvets.2022.843744

Publication

Frontiers in veterinary science
ISSN: 2297-1769
NlmUniqueID: 101666658
Country: Switzerland
Language: English
Volume: 9
Pages: 843744

Researcher Affiliations

Peyrecave-Capo, Xavier
  • Equine Department, Faculty of Veterinary Medicine, VetAgro-Sup, University of Lyon, Marcy l'Etoile, France.
Saulnier, Nathalie
  • Vetbiobank, Marcy l'Etoile, France.
Maddens, Stéphane
  • Vetbiobank, Marcy l'Etoile, France.
Gremillet, Bérengère
  • Department of Clinical Sciences, Veterinary Medicine, University of Liège, Sart-Tilman, Liège, Belgium.
Desjardins, Isabelle
  • Equine Department, Faculty of Veterinary Medicine, VetAgro-Sup, University of Lyon, Marcy l'Etoile, France.

Conflict of Interest Statement

SM and NS are employees and shareholders of Vetbiobank at the time of the submission for publication. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

This article includes 62 references
  1. Agrawal VB, Tsai RJ. Corneal epithelial wound healing.. Indian J Ophthalmol (2003) 51:5.
    pubmed: 12701857
  2. Burling K, Seguin MA, Marsh P. Effect of topical administration of epidermal growth factor on healing of corneal epithelial defects in horses.. Am J Vet Res (2000) 61:1150–5.
    doi: 10.2460/ajvr.2000.61.1150pubmed: 10976751google scholar: lookup
  3. Brook I, Frazier EH. Aerobic and anaerobic microbiology of keratitis.. Ann Ophthalmol - Glauc (1999) 31:21–6.
  4. Brooks DE. Inflammatory stromal keratopathies: medical management of stromal keratomalacia, stromal abscesses, eosinophilic keratitis, and band keratopathy in the horse.. Vet Clin North Am Equine Pract (2004) 20:345–60.
    doi: 10.1016/j.cveq.2004.04.007pubmed: 15271427google scholar: lookup
  5. Plummer CE. Corneal response to injury and infection in the horse.. Vet Clin North Am Equine Pract (2017) 33:439–63.
    doi: 10.1016/j.cveq.2017.07.002pubmed: 28985985google scholar: lookup
  6. Brown SI, Bloomfield S, Pearce DB, Tragakis M. Infections with the therapeutic soft lens.. Arch Ophthalmol (1974) 91:275–7.
    doi: 10.1001/archopht.1974.03900060285007pubmed: 4621152google scholar: lookup
  7. Monod M, Capoccia S, Léchenne B, Zaugg C, Holdom M, Jousson O. Secreted proteases from pathogenic fungi.. Int J Med Microbiol (2002) 292:405–19.
    doi: 10.1078/1438-4221-00223pubmed: 12452286google scholar: lookup
  8. Scardovi C, De Felice GP, Gazzaniga A. Epidermal growth factor in the topical treatment of traumatic corneal ulcers.. Ophthalmologica (1993) 206:119–24.
    doi: 10.1159/000310376pubmed: 8272333google scholar: lookup
  9. Utter ME, Davidson EJ, Wotman KL. Clinical features and outcomes of severe ulcerative keratitis with medical and surgical management in 41 horses (2000–2006).. Equine Vet Educ (2009) 21:321–7.
    doi: 10.2746/095777309X400270google scholar: lookup
  10. Chiang CC, Chen WL, Lin JM, Tsai YY. Allogeneic serum eye drops for the treatment of persistent corneal epithelial defect.. Eye (2009) 23:290.
    doi: 10.1038/sj.eye.6703079pubmed: 18188173google scholar: lookup
  11. Shen EP, Hu FR, Lo SC. Comparison of corneal epitheliotrophic capacity among different human blood–derived preparations.. Cornea (2011) 30:208.
    doi: 10.1097/ICO.0b013e3181eadb67pubmed: 21045671google scholar: lookup
  12. Yoon KC, Im SK, Park YG, Jung YD, Yang SY, Choi J. Application of umbilical cord serum eyedrops for the treatment of dry eye syndrome.. Cornea (2006) 25:268–72.
    doi: 10.1097/01.ico.0000183484.85636.b6pubmed: 16633024google scholar: lookup
  13. Erdem E, Yagmur M, Harbiyeli I, Taylan-Sekeroglu H, Ersoz R. Umbilical cord blood serum therapy for the management of persistent corneal epithelial defects.. Int J Ophthalmol (2014) 7:807–10.
    doi: 10.3980/j.issn.2222-3959.2014.05.12pmc: PMC4206885pubmed: 25349797google scholar: lookup
  14. Versura P, Buzzi M, Giannaccare G. Targeting growth factor supply in keratopathy treatment: comparison between maternal peripheral blood and cord blood as sources for the preparation of topical eye drops.. Blood Transfus (2016) 14:145–51.
    doi: 10.2450/2015.0020-15pmc: PMC4781782pubmed: 26192781google scholar: lookup
  15. Yoon KC, Choi W, You IC, Choi J. Application of umbilical cord serum eyedrops for recurrent corneal erosions.. Cornea (2011) 30:744–8.
    doi: 10.1097/ico.0b013e31820d850fpubmed: 21436685google scholar: lookup
  16. Ehrhart J, Sanberg PR, Garbuzova-Davis S. Plasma derived from human umbilical cord blood: potential cell-additive or cell-substitute therapeutic for neurodegenerative diseases.. J Cell Mol Med (2018) 22:6157–66.
    doi: 10.1111/jcmm.13898pmc: PMC6237605pubmed: 30334335google scholar: lookup
  17. Buzzi M, Versura P, Grigolo B. Comparison of growth factor and interleukin content of adult peripheral blood and cord blood serum eye drops for cornea and ocular surface diseases.. Transfus Apher Sci (2018) 57:549–55.
    doi: 10.1016/j.transci.2018.06.001pubmed: 29929885google scholar: lookup
  18. Vajpayee RB, Mukerji N, Tandon R. Evaluation of umbilical cord serum therapy for persistent corneal epithelial defects.. Br J Ophthalmol (2003) 87:1312–6.
    doi: 10.1136/bjo.87.11.1312pmc: PMC1771905pubmed: 14609821google scholar: lookup
  19. Denys M, Léon Léon A, Robert C. Biosafety evaluation of equine umbilical cord-derived mesenchymal stromal cells by systematic pathogen screening in peripheral maternal blood and paired UC-MSCs.. Biopreservation Biobanking (2020) 18:73–81.
    doi: 10.1089/bio.2019.0071pubmed: 31904273google scholar: lookup
  20. Ionita CR, Troillet AR, Vahlenkamp TW, Winter K, Brehm W, Ionita J-C. Comparison of humoral insulin-like growth factor-1, platelet-derived growth factor-BB, transforming growth factor-β1, and interleukin-1 receptor antagonist concentrations among equine autologous blood-derived preparations.. Am J Vet Res (2016) 7:898–905.
    doi: 10.2460/ajvr.77.8.898pubmed: 27463555google scholar: lookup
  21. Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application.. Ophthalmology (1999) 106:1984–9.
    doi: 10.1016/S0161-6420(99)90412-8pubmed: 10519596google scholar: lookup
  22. Ohashi Y, Motokura M, Kinoshita Y. Presence of epidermal growth factor in human tears.. Invest Ophthalmol Vis Sci (1989) 30:1879–82.
    pubmed: 2788149
  23. McClintock JL, Ceresa BP. Transforming growth factor-α enhances corneal epithelial cell migration by promoting EGFR recycling.. Invest Ophthalmol Vis Sci (2010) 51:3455–461.
    doi: 10.1167/iovs.09-4386pmc: PMC2904005pubmed: 20181835google scholar: lookup
  24. Kamiyama K, Iguchi I, Wang X, Imanishi J. Effects of PDGF on the migration of rabbit corneal fibroblasts and epithelial cells.. Cornea (1998) 17:315–25.
    doi: 10.1097/00003226-199805000-00010pubmed: 9603389google scholar: lookup
  25. Haber M, Cao Z, Panjwani N, Bedenice D, Li WW, Provost PJ. Effects of growth factors (EGF, PDGF-BB and TGF-β1) on cultured equine epithelial cells and keratocytes0: implications 0for wound healing.. Vet Ophthalmol (2003) 6:211–7.
    doi: 10.1046/j.1463-5224.2003.00296.xpubmed: 12950652google scholar: lookup
  26. Nishida T. Translational research in corneal epithelial wound healing.. Eye Contact Lens (2010) 36:300–4.
    doi: 10.1097/ICL.0b013e3181f0416d0pubmed: 20724848google scholar: lookup
  27. Lee HK, Lee JH, Kim M, Kariya Y, Miyazaki K, Kim EK. Insulin-like growth factor-1 induces migration and expression of laminin-5 in cultured human corneal epithelial cells.. Invest Ophthalmol Vis Sci (2006) 47:873–82.
    doi: 10.1167/iovs.05-0826pubmed: 16505019google scholar: lookup
  28. Trosan P, Svobodova E, Chudickova M, Krulova M, Zajicova A, Holan V. The key role of insulin-like growth factor I in limbal stem cell differentiation and the corneal wound-healing process.. Stem Cells Dev (2012) 21:3341–50.
    doi: 10.1089/scd.2012.0180pmc: PMC3516427pubmed: 22873171google scholar: lookup
  29. Ljubimov AV, Saghizadeh M. Progress in corneal wound healing.. Prog Retin Eye Res (2015) 49:17–45.
    doi: 10.1016/j.preteyeres.2015.07.002pmc: PMC4651844pubmed: 26197361google scholar: lookup
  30. Yoon KC. Use of umbilical cord serum in ophthalmology.. Chonnam Med J (2014) 50:82–5.
    doi: 10.4068/cmj.2014.50.3.82pmc: PMC4276795pubmed: 25568842google scholar: lookup
  31. Nishida T, Chikama T, Morishige N, Yanai R, Yamada N, Saito J. Persistent epithelial defects due to neurotrophic keratopathy treated with a substance p-derived peptide and insulin-like growth factor 1.. Jpn J Ophthalmol (2007) 51:442–7.
    doi: 10.1007/s10384-007-0480-zpubmed: 18158595google scholar: lookup
  32. Ambroziak AM, Szaflik J, Szaflik JP, Ambroziak M, Witkiewicz J, Skopiński P. Immunomodulation on the ocular surface: a review.. Cent-Eur J Immunol (2016) 41:195–208.
    doi: 10.5114/ceji.2016.60995pmc: PMC4967654pubmed: 27536206google scholar: lookup
  33. Brown NAP, Bron AJ, Harding JJ, Dewar HM. Nutrition supplements and the eye.. Eye (1998) 12:127–33.
    doi: 10.1038/eye.1998.21pubmed: 9614529google scholar: lookup
  34. Deshpande AA, Tabatabay C, Hughes PM, Gurny R. Therapeutic applications of retinoids in ophthalmology.. Int J Pharm (1997) 157:1–15.
    doi: 10.1016/S0378-5173(97)00251-2google scholar: lookup
  35. Versura P, Profazio V, Buzzi M. Efficacy of standardized and quality-controlled cord blood serum eye drop therapy in the healing of severe corneal epithelial damage in dry eye.. Cornea (2013) 32:412–8.
    doi: 10.1097/ICO.0b013e3182580762pubmed: 22955120google scholar: lookup
  36. Geerling G, MacLennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders.. Brit J Ophtalmol (2004) 88:1467–74.
    pmc: PMC1772389pubmed: 15489495
  37. Rebhun WC. Chronic corneal epithelial erosions in horses.. Vet Med Sm Anim Clin (1983) 78:1635.
  38. Crispin SM. Tear-deficient and evaporative dry eye syndromes of the horse.. Vet Ophthalmol (2000) 3:87–92.
    doi: 10.1046/j.1463-5224.2000.3230087.xpubmed: 11397288google scholar: lookup
  39. Yamada J, Reza Dana M, Sotozono C, Kinoshita S. Local suppression of IL-1 by receptor antagonist in the rat model of corneal alkali injury.. Exp Eye Res (2003) 76:161–7.
    doi: 10.1016/S0014-4835(02)00293-2pubmed: 12565803google scholar: lookup
  40. Biswas PS, Banerjee K, Zheng M, Rouse BT. Counteracting corneal immunoinflammatory lesion with interleukin-1 receptor antagonist protein.. J Leukoc Biol (2004) 76:868–75.
    doi: 10.1189/jlb.0504280pubmed: 15258192google scholar: lookup
  41. Davies BW, Panday V, Caldwell M, Scribbick F, Reilly CD. Effect of topical immunomodulatory interleukin 1 receptor antagonist therapy on corneal healing in new zealand white rabbits (Oryctolagus cunniculus) after photorefractive keratectomy.. Arch Ophthalmol (2011) 129:909–13.
    doi: 10.1001/archophthalmol.2011.168pubmed: 21746982google scholar: lookup
  42. Badami KG, McKellar M. Allogeneic serum eye drops: time these became the norm?. Br J Ophthalmol (2012) 96:1151–2.
    doi: 10.1136/bjophthalmol-2012-301668pubmed: 22539749google scholar: lookup
  43. Murphy CJ, Marfurt CF, McDermott A. Spontaneous chronic corneal epithelial defects (SCCED) in dogs: clinical features, innervation, and effect of topical sp, with or without IGF-1.. Invest Ophthalmol Vis Sci (2001) 42:2252–61.
    pubmed: 11527938
  44. Heyworth P, Morlet N, Rayner S, Hykin P, Dart J. Natural history of recurrent erosion syndrome - a 4 year review of 117 patients.. Br J Ophthalmol (1998) 82:26–8.
    doi: 10.1136/bjo.82.1.26pmc: PMC1722350pubmed: 9536875google scholar: lookup
  45. Bentley E. Spontaneous chronic corneal epithelial defects in dogs: a review.. J Am Anim Hosp Assoc (2005) 41:158–65.
    doi: 10.5326/0410158pubmed: 15870249google scholar: lookup
  46. Lin SR, Aldave AJ, Chodosh J. Recurrent corneal erosion syndrome.. Br J Ophthalmol (2019) 103:1204–8.
    doi: 10.1136/bjophthalmol-2019-313835pubmed: 30760455google scholar: lookup
  47. Cooley PL, Wyman M. Indolent-like corneal ulcers in 3 horses.. J Am Vet Med Assoc (1986) 188:295–7.
    pubmed: 3949604
  48. Hakanson NE, Dubielzig RR. Chronic superficial corneal erosions with anterior stromal sequestration in three horses.. Ophthalmic Lit (1995) 1:60.
  49. Cutler TJ. Corneal epithelial disease.. Vet Clin North Am Equine Pract (2004) 20:319–43.
    doi: 10.1016/j.cveq.2004.04.014pubmed: 15271426google scholar: lookup
  50. Malalana F. Ophthalmologic disorders in aged horses.. Vet Clin North Am Equine Pract (2016) 32:249–61.
    doi: 10.1016/j.cveq.2016.04.004pubmed: 27329494google scholar: lookup
  51. Lassaline-Utter M, Cutler TJ, Michau TM, Nunnery CM. Treatment of non-healing corneal ulcers in 60 horses with diamond burr debridement (2010–2013).. Vet Ophthalmol (2014) 17:76–81.
    doi: 10.1111/vop.12148pubmed: 24506287google scholar: lookup
  52. Sharma N, Goel M, Velpandian T, Titiyal JS, Tandon R, Vajpayee RB. Evaluation of umbilical cord serum therapy in acute ocular chemical burns.. Invest Ophthalmol Vis Sci (2011)4 52:1087–92.
    doi: 10.1167/iovs.09-4170pubmed: 20538982google scholar: lookup
  53. Ziakas NG, Boboridis KG, Terzidou C. Long-term follow up of autologous serum treatment for recurrent corneal erosions.. Clin Experiment Ophthalmol (2010) 38:683–7.
    doi: 10.1111/j.1442-9071.2010.02304.xpubmed: 20456438google scholar: lookup
  54. Soni NG, Jeng BH. Blood-derived topical therapy for ocular surface diseases.. Br J Ophthalmol (2016) 100:22–7.
    doi: 10.1136/bjophthalmol-2015-306842pubmed: 26178904google scholar: lookup
  55. Nugent RB, Lee GA. Ophthalmic use of blood-derived products.. Surv Ophthalmol (2015) 60:406–34.
    doi: 10.1016/j.survophthal.2015.03.003pubmed: 26077627google scholar: lookup
  56. Yoon KC, You IC, Im SK, Jeong TS, Park YG, Choi J. Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis.. Ophthalmology (2007) 114:1637–42.
    doi: 10.1016/j.ophtha.2006.12.014pubmed: 17382396google scholar: lookup
  57. Neaderland MH, Riis RC, Rebhun WC, Erb HN. Healing of experimentally induced corneal ulcers in horses.. Am J Vet Res (1987) 48:427–30.
    pubmed: 3565900
  58. Giannacare G, Carnevali A, Senni C, Logozzo L, Scorzia V. Umbilical cord blood and serum for the treatment of ocular diseases: a comprehensive review.. Ophthalmol Ther (2020) 9:235–48.
    doi: 10.1007/s40123-020-00239-9pmc: PMC7196109pubmed: 32107737google scholar: lookup
  59. Karamichos D, Hutcheon AEK, Zieske JD. Reversal of fibrosis by TGF-β3 in a 3D in vitro model.. Exp Eye Res (2014) 124:31–6.
    doi: 10.1016/j.exer.2014.04.020pmc: PMC4065812pubmed: 24800655google scholar: lookup
  60. Hung Y, Elder MJ, Rawstron JA, Badami KG. A retrospective crossover study of autologous and allogeneic serum eye drops for the management of ocular surface disease.. Transfus Med (2019) 29:69–71.
    doi: 10.1111/tme.12572pubmed: 30585367google scholar: lookup
  61. Lekhanont K, Jongkhajornpong P, Choubtum L, Chuckpaiwong V. Topical 100% serum eye drops for treating corneal epithelial defect after ocular surgery.. BioMed Research International (2013) 2013:521315.
    doi: 10.1155/2013/521315pmc: PMC3745890pubmed: 23984378google scholar: lookup
  62. Gupta A, Monroy D, Ji Z, Yoshino K, Huang A, Pflugfelder SC. Transforming growth factor beta-1 and beta-2 in human tear fluid.. Curr Eye Res (1996) 15:605–14.
    doi: 10.3109/02713689609008900pubmed: 8670763google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.